Loading…
← CockpitCompetitor Analysis › 140410.KS Mezzion Pharma Co., Ltd.Open in the cockpit ↗

Mezzion Pharma Co., Ltd.140410.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biotech developing udenafil, a PDE5-inhibitor drug studied for single-ventricle heart disease in Fontan-procedure patients.

Momentum leader 82
Mkt cap
$1.43B
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$5.70M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-54.3 pp
WACC 7.2%
Hurdle
n/a
no reverse DCF
Close · KRW₩64,800
1D+1.6%
1W-4.8%
1M+10.4%
3M-5.7%
6M-14.6%
YTD-28.1%
1Y-6.0%
ATR %6.8%
52w lowhigh64.0% off high

What Mezzion Pharma does

Korean biotech developing udenafil, a PDE5-inhibitor drug studied for single-ventricle heart disease in Fontan-procedure patients.

Has no approved product of its own, so it relies on raising money from investors while its trials proceed. Udenafil already sells in some countries for erectile dysfunction, which lets it draw on an existing safety record for the heart indication.

Products and services

  • Udenafil (Fontan/single-ventricle heart disease)
  • Other PDE5-inhibitor indications

Customers

  • US/global pediatric-cardiology patients (via trial

Where it sits in the supply chain

  • Biotechnology
  • Cardiovascular drug development
  • US/global clinical development

What could go right

  • FDA approval/commercial launch

What could go wrong

  • Clinical-trial/regulatory setback risk
  • Single-drug pipeline concentration

Moat: narrow (IP / patents). Patented use of udenafil in a rare pediatric heart condition, backed by US clinical trial data.

Headquarters: Seoul, South Korea · Employees: 18

Mezzion Pharma at a glance

Size Mezzion Pharma (140410.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 183rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩64,800 on 18 Nov 2026.

Performance Over six months the shares fell 14.6%, against -14.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 12.5% over the last twelve months (peer median +9.6%); the operating margin is -210.6% (peer median 10.9%).

Valuation It trades at 216.0× enterprise value to sales against a peer median of 3.6× (2nd most expensive of 19).

Capital Return on invested capital runs 54.3 points below its cost of capital (7.2% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026140410.KS 88Peer median 87
Six months, rebased to 100: Mezzion Pharma against the median of its 20 peers (local-currency closes).

Mezzion Pharma financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩8.72B₩7.91B₩8.61B₩31.7B₩30.7B
Revenue growth—-8%-73%+3%—
Gross profit₩675M₩464M₩953M₩2.59B-₩1.60B
EBITDA-₩17.5B-₩15.8B-₩13.3B-₩12.9B-₩21.7B
Net income-₩29.7B-₩34.9B-₩19.5B-₩12.7B-₩36.3B
Free cash flow-₩24.3B-₩16.7B-₩19.1B-₩11.6B-₩12.8B
Capital expenditure₩7.27B₩13.3B₩13.5B₩11.9B₩1.76B
Total debt₩13.1B₩11.9B₩1.62B₩2.24B₩3.71B

Quarterly statements and history in the cockpit →

Mezzion Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-20%0%310210MARKSANS4516DMRAPAHC002626CORONA002020141080298380226950603235NANO600572300181068760688293SRPT140410.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Mezzion Pharma is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%0×25,000×50,000×75,000×310210MARKSANS4516002626141080298380NANO688293SRPT140410.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mezzion Pharma is the large dot.

Mezzion Pharma competitors and peer comparison

How Mezzion Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mezzion Pharma against its 20 peers (data as of 18 Nov 2026)
Measure140410.KSPeer medianRank in peer set
1-month return+10.4%-4.1%4th highest of 20
6-month return-14.6%-14.7%10th highest of 20
Distance from 52-week high-64.0%-40.8%4th lowest of 20
Revenue growth (TTM)+12.5%+9.6%9th highest of 19
Operating margin-210.6%10.9%5th lowest of 19
EV / Sales216.0×3.6×2nd most expensive of 19
ROIC minus cost of capital-54.3 pp-0.5 pp7th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%216.0×n/an/a
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%85,633.6×n/an/a
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%3.8×31.0%+16.6%
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%1.4×-6.4%+12.7%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%3.1×n/an/a
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%8.9×36.3%+16.6%
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%17.0×n/an/a
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%46.5×n/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%3.5×-4.9%+0.2%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%0.9×-6.8%+32.4%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a

Questions

Which companies are Mezzion Pharma's closest peers?
The cockpit's peer set: Voronoi (310210.KS), Marksans Pharma (MARKSANS.NS), Nippon Shinyaku (4516.T), Damora Therapeutics (DMRA), Phibro Animal Health (PAHC), Xiamen Kingdomway (002626.SZ), Corona Remedies (CORONA.NS), Zhejiang Jingxin Pharmaceutical (002020.SZ).
Is Mezzion Pharma expensive compared with its peers?
On ev / sales it trades at 216.0× against a peer median of 3.6×, 2nd most expensive of 19 in its peer set.
How has Mezzion Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -14.6% against -14.7% for the median peer; over one year -6.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.